Ovarian cancer is often diagnosed in late stages with few treatment options and poor long-term prognosis. New clinical tools for early detection of ovarian malignancies will significantly help reduce mortality and improve current long-term survival rates. The objective of this work was to identify ovarian tumor-specific single-stranded DNA aptamers that bind to malignant ovarian tumor cells and internalize with high affinity and specificity. Aptamers can identify unique tumor biomarkers, can aid in early detection and diagnosis of neoplastic disorders, and can be functionalized by conjugation to small molecules. To identify aptamers from random single-stranded DNA pools (60 bases long), we used whole Cell-SELEX (systematic evolution of ligands by exponential enrichment) to enrich and isolate tumor-specific aptamers that bind to tumor-specific receptors in their native state on the cell surface. Next-Generation sequencing identified seven novel aptamers and detailed analyses of three are described. Aptamers bound to, and were internalized by, target Caov-3 cell populations, but not nontarget nonmalignant ovarian epithelial HOSE 6-3 cells or multiple other epithelial tumor cell lines. Furthermore, aptamers showed unique binding affinities with apparent dissociation constants (Kd) measuring in the submicromolar range supporting their physiological relevance and potential use in clinical applications.
Get full access to this article
View all access options for this article.
References
1.
ChoiM, FullerCD, ThomasCRJr. and WangSJ. (2008). Conditional survival in ovarian cancer: results from the SEER dataset 1988–2001. Gynecol Oncol, 109:203–209.
2.
KroepJR. (2012). Advances in epithelial ovarian cancer therapy. Curr Pharm Des, 18:3735–3740.
3.
BicakuE, XiongY, MarchionDC, ChonHS, SticklesXB, et al. (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer, 106:1967–1975.
4.
ConicI, DimovI, Tasic-DimovD, DjordjevicB and StefanovicV. (2011). Ovarian epithelial cancer stem cells. ScientificWorldJournal, 11:1243–1269.
5.
DubeauL. (2008). The cell of origin of ovarian epithelial tumours. Lancet Oncol, 9:1191–1197.
6.
CohenJG, WhiteM, CruzA and Farias-EisnerR. (2014). In 2014, can we do better than CA125 in the early detection of ovarian cancer?. World J Biol Chem, 5:286–300.
7.
HellstromI and HellstromKE. (2008). SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol, 622:15–21.
8.
SoraceJM and ZhanM. (2003). A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics, 4:24.
9.
JacobsI, OramD, FairbanksJ, TurnerJ, FrostC, et al. (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97:922–929.
10.
MooreRG, McMeekinDS, BrownAK, DiSilvestroP, MillerMC, et al. (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol, 112:40–46.
11.
ZhangZ, BastRCJr., YuY, LiJ, SokollLJ, et al. (2004). Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 64:5882–5890.
12.
YipP, ChenTH, SeshaiahP, StephenLL, Michael-BallardKL, et al. (2011). Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One, 6:e29533.
ZhuJ, HuangH, DongS, GeL and ZhangY. (2014). Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics, 4:931–944.
15.
BrodyEN and GoldL. (2000). Aptamers as therapeutic and diagnostic agents. J Biotechnol, 74:5–13.
16.
ZhouW, HuangPJ, DingJ and LiuJ. (2014). Aptamer-based biosensors for biomedical diagnostics. Analyst, 139:2627–2640.
17.
ShumKT, ZhouJ and RossiJJ. (2013). Nucleic acid aptamers as potential therapeutic and diagnostic agents for lymphoma. J Cancer Ther, 4:872–890.
18.
JalalianSH, TaghdisiSM, Shahidi HamedaniN, KalatSA, LavaeeP, et al. (2013). Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci, 50:191–197.
19.
CunninghamETJr., AdamisAP, AltaweelM, AielloLP, BresslerNM, et al. (2005). A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 112:1747–1757.
20.
ResearchB. (2013). Aptamers market—technology trend analysis by applications—therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, research applications with market landscape analysis—global forecasts to 2018. Available at www.marketsandmarkets.com.
21.
NgEW and AdamisAP. (2006). Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci, 1082:151–171.
22.
NgEW, ShimaDT, CaliasP, CunninghamETJr., GuyerDR, et al. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 5:123–132.
23.
TolentinoMJ, DennrickA, JohnE and TolentinoMS. (2014). Drugs in phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Investig Drugs:24:183–199.
24.
BieseckerG, DihelL, EnneyK and BendeleRA. (1999). Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology, 42:219–230.
25.
MallikaratchyPR, RuggieroA, GardnerJR, KuryavyiV, MaguireWF, et al. (2011). A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res, 39:2458–2469.
26.
SoundararajanS, ChenW, SpicerEK, Courtenay-LuckN and FernandesDJ. (2008). The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res, 68:2358–2365.
27.
GirvanAC, TengY, CassonLK, ThomasSD, JuligerS, et al. (2006). AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther, 5:1790–1799.
28.
ZhangX, ZhangJ, MaY, PeiX, LiuQ, et al. (2014). A cell-based single-stranded DNA aptamer specifically targetsgastric cancer. Int J Biochem Cell Biol, 46:1–8.
29.
IwamuraT, KatsukiT and IdeK. (1987). Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19–9. Jpn J Cancer Res, 78:54–62.
30.
TsaoSW, MokSC, FeyEG, FletcherJA, WanTS, et al. (1995). Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res, 218:499–507.
31.
ZhanSB and ZengY. (2013). [Recent progress on SELEX and its applications]. Bing Du Xue Bao, 29:573–577.
32.
DanielsDA, ChenH, HickeBJ, SwiderekKM and GoldL. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A, 100:15416–15421.
33.
BuickRN, PullanoR and TrentJM. (1985). Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res, 45:3668–3676.
34.
AbouzeidAH, PatelNR and TorchilinVP. (2014). Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm, 464:178–184.
35.
FurlongMT, HoughCD, Sherman-BaustCA, PizerES and MorinPJ. (1999). Evidence for the colonic origin of ovarian cancer cell line SW626. J Natl Cancer Inst, 91:1327–1328.
36.
HennessyBT, ColemanRL and MarkmanM. (2009). Ovarian cancer. Lancet, 374:1371–1382.
37.
BeaufortCM, HelmijrJC, PiskorzAM, HoogstraatM, Ruigrok-RitstierK, et al. (2014). Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One, 9:e103988.
38.
HerfsM, YamamotoY, LauryA, WangX, NucciMR, et al. (2012). A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A, 109:10516–10521.
39.
MasiakosPT, MacLaughlinDT, MaheswaranS, TeixeiraJ, FullerAFJr., et al. (1999). Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res, 5:3488–3499.
40.
SaadAF, HuW and SoodAK. (2010). Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer, 1:277–290.
41.
CrumCP, DrapkinR, KindelbergerD, MedeirosF, MironA, et al. (2007). Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res, 5:35–44.
42.
BellC, LynamE, LandfairDJ, JanjicN and WilesME. (1999). Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim, 35:533–542.
43.
RuckmanJ, GreenLS, BeesonJ, WaughS, GilletteWL, et al. (1998). 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem, 273:20556–20567.
44.
BatesPJ, KahlonJB, ThomasSD, TrentJO and MillerDM. (1999). Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem, 274:26369–26377.
45.
IresonCR and KellandLR. (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther, 5:2957–2962.
46.
Van SimaeysD, Lopez-ColonD, SefahK, SutphenR, JimenezE, et al. (2010). Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX. PLoS One, 5:e13770.
47.
CerchiaL, EspositoCL, CamoraniS, RienzoA, StasioL, et al. (2012). Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther, 20:2291–2303.
48.
TangZ, ShangguanD, WangK, ShiH, SefahK, et al. (2007). Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem, 79:4900–4907.
49.
ShangguanD, MengL, CaoZC, XiaoZ, FangX, et al. (2008). Identification of liver cancer-specific aptamers using whole live cells. Anal Chem, 80:721–728.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
